- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
ABBVIE / SHIRE
M.7339
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Disclaimer :
The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.
SECTION 1.2
Description of the concentration
This notified transaction concerns the proposed acquisition by AbbVie Inc. ("AbbVie") of sole control of Shire plc ("Shire"). The transaction constitutes a concentration for the purpose of Article 3(1)(b) of Council Regulation (EC) No. 139/2004.
AbbVie is global, research-based biopharmaceutical company, launched as an independent biopharmaceutical company in January 2013 following the separation of the innovative pharmaceuticals business of Abbott Laboratories. The principal business of AbbVie is the discovery, development, manufacture and sale of proprietary pharmaceutical products.
Shire is a global specialty biopharmaceutical company. Shire's pharmaceuticals business is divided into four principal business segments: (1) Rare Diseases; (2) Neuroscience; (3) Gastrointestinal; and (4) Internal Medicine.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.